

**Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest  
and Waiver under 18 U.S.C. §208(b)(3)**

**David L. DeMets, Ph.D.**

**Committee:** Cardiovascular and Renal Drugs Advisory  
Committee

**Meeting Date:** April 26, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to agenda item concerning the discussion of the Agency's draft recommendations for re-labeling of anti-hypertensive drugs for outcome claims, as a follow-up to the committee's meeting on June 15, 2005, where the committee discussed class labeling of antihypertensive drugs based on the proximity of their data to outcome trials, I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).

<b>Type of Interest</b>	<b>Nature</b>	<b>Magnitude</b>
Unrelated Consulting	Affected Firm	Less than \$10,001 per year.
Unrelated Consulting	Affected Firm	Less than \$10,001 per year.
Member of Data Safety Monitoring Board	Affected Firm	Less than \$10,001 per year.
Member of Data Safety Monitoring Board	Affected Firm	Less than \$10,001 per year.
Member of Data Safety Monitoring Board	Affected Firm	Less than \$10,001 per year.
Member of Data Safety Monitoring Board	Affected Firm	Less than \$10,001 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

\_\_\_\_\_/S/\_\_\_\_\_  
Signature of SGE

\_\_\_\_\_/3/29/06\_\_\_\_\_  
Date